公司公告 - 公司计划于2025年1月28日下午5点（美国东部时间）发布2025财年第一季度财报 [1] - 公司将于2025年1月29日上午9点（美国东部时间）举行与证券分析师的网络直播，内容包括执行摘要和详细评论 [1] - 网络直播的幻灯片演示文稿将同时发布在公司网站的投资者关系部分 [1] - 网络直播和辅助材料将在公司网站上存档12个月 [3] 公司简介 - 公司是一家全球添加剂和特种成分公司，专注于环境、社会和治理（ESG） [4] - 公司服务于广泛的消费和工业市场，包括建筑涂料、建筑、能源、食品和饮料、个人护理和制药 [4] - 公司拥有约3200名员工，包括知名科学家、研究化学家、工程师和工厂操作员，致力于为100多个国家的客户提供实用、创新和优雅的解决方案 [4] 参与人员 - 网络直播的参与者包括公司董事长兼首席执行官Guillermo Novo、高级副总裁兼首席财务官Kevin Willis、高级副总裁兼特种添加剂总经理Dago Caceres、高级副总裁兼生命科学和中间体总经理Alessandra Faccin、高级副总裁兼个人护理总经理Jim Minicucci、财务副总裁兼投资者关系总监William Whitaker [7]

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:89bio, Inc. (ETNB) is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days.Altice USA, Inc. (ATUS) is a broadband communications and video services provider. The Zacks Consensus Estimate for its current year earnings has been revised 250% downward over the last 60 days.Ashland Inc. (ASH) is a additives and specialty ingredients prov ...

公司核心观点 - Ashland Inc.宣布已签署最终协议，将其Avoca业务出售给Mane公司 交易预计将在2025年第一季度完成，需满足惯例的交割条件 [1] 公司业务描述 - Avoca业务是香精固定剂领域的强大参与者，拥有专门的团队和吸引人的制造能力，以满足客户需求 Avoca业务线代表Ashland之前收购Pharmachem的最后一个实体 [2][5] - Avoca业务供应Sclareolide（一种香精固定剂），并从北卡罗来纳州和威斯康星州的两家生产设施提供一系列合同制造能力 [5] 公司管理层评论 - Ashland的董事长兼首席执行官Guillermo Novo对Avoca员工的奉献和承诺表示感谢 [2] 交易相关信息 - Squire Patton Boggs担任Ashland的法律顾问 [6] 公司背景 - Ashland Inc.是一家全球添加剂和特种成分公司，致力于环境、社会和治理(ESG) 公司为建筑涂料、建筑、能源、食品和饮料、个人护理和制药等多个消费者和工业市场的客户提供服务 约有3,200名热情、坚韧的解决者致力于为客户开发实用、创新和优雅的解决方案，服务超过100个国家 [8] - Mane公司成立于1871年，是全球领先的香精和香料生产商和供应商 公司由Mane家族的五代人拥有和管理 [9] - Mane在全球拥有29个生产设施，超过79个站点分布在40多个国家，雇用超过8,000名员工 公司是法国第一家，全球第五大香精和香料生产商，并被认为是行业内增长最快的公司 [10]

As an investment analyst with 3 years of experience in the finance sector, I specialize in analyzing market trends, conducting thorough financial assessments, and providing actionable investment recommendations. My expertise lies in momentum and factor investing, where I utilize a blend of quantitative and qualitative methods to identify opportunities and manage risks.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate a ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Ashland Inc. (ASH) : is a additive and specialty ingredients provider. The Zacks Consensus Estimate for its current year earnings has been revised 15% downward over the last 60 days.Baidu, Inc. (BIDU) is an online marketing and cloud services provider. The Zacks Consensus Estimate for its current year earnings has been revised 9% downward over the last 60 days.Evolent Health, Inc. (EVH) is a health service company. The Zacks Consensus ...

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell diseaseFRONTIER4 interim phase 3 results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks for patients with haemophilia A with or without inhibitorsExplorer7 phase 3 study results evaluating the safety profile and efficacy of concizumab in patients with haemophilia A or B with inhibitors, with or without target joints at baseline Bagsvær ...

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American So ...

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company’s oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66th Amer ...

SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, ...

75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that additional NEXICART-1 NXC-201 clinical data in relaps ...